


The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~The use~~ A method of treating or preventing a disorder in which the blocking of purine receptors is beneficial, the method comprising administration to a subject in need of such treatment an effective dose of a compound of formula (1):



(I)

wherein

R₁ is optionally substituted C₁-C₆alkyl, C₂-C₆alkenyl, or C₂-C₆alkynyl, or -NR₆R₇, -OR₈, -SR₉ or halogen;

R₂ is optionally substituted aryl or heteroaryl attached via a carbon atom;

R₃ is H; optionally substituted C₁-C₆alkyl, C₂-C₆alkenyl, C₂alkynyl, or C₃-C₇ cycloalkyl, halogen; OH or OR₁₀;

R₄ is H, optionally substituted C₁-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, C₃-C₇ cycloalkyl, aryl or heteroaryl,

R₅ is H or optionally substituted C₁-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, or C₃-C₇cycloalkyl; or R₄ and R₅ together form a 5 or 6-membered heterocyclic ring;

R₆ is H or optionally substituted C₁-C₃alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, or C₃-C₇ cycloalkyl;

R₇, R₈, R₉ and R₁₀ are optionally substituted C₁-C₃alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, or C₃-C₇ cycloalkyl or

R₆ and R₇ together form a 5 or 6-membered heterocyclic ring;

~~and or a pharmaceutically acceptable salts and prodrugs salt or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors is beneficial.~~

2. (Currently Amended) ~~The use~~ method as claimed in claim 1 wherein R₁ is halogen,

optionally substituted C₁-C₃alkyl, C₂-C₃alkenyl, or -NR₆R₇, -OR₈, -SR₉; wherein R₆ is H or optionally substituted C₁-C₃alkyl, and R₇, R₈, and R₉ are C₁-C₃alkyl, or R₆ and R₇ together form a 5 or 6-membered heterocyclic ring.

3. (Currently Amended) The ~~use~~method as claimed in claim 1 wherein R₁ is methyl, ethyl, n- or iso-propyl, trifluoromethyl, allyl, cyclopropyl, chloro, bromo or fluoro.

4. (Currently Amended) The ~~use~~method as claimed in claim 1 wherein R₁ is -NR₆R₇, -OR₈, -SR₉; wherein R₆ is hydrogen, methyl, ethyl, n- or iso-propyl, trifluoromethyl, or allyl; R₇ is methyl, ethyl, n- or iso-propyl; R₈ and R₉ are methyl, ethyl, n- or iso-propyl, trifluoromethyl or allyl.

5. (Currently Amended) The ~~use~~method as claimed in claim 1 wherein R₁ is -NHCH₃.

6. (Currently Amended) The ~~use~~method as claimed in ~~any of the preceding claims~~ claim 1 wherein R₂ is optionally substituted phenyl.

7. (Currently Amended) The ~~use~~method as claimed in ~~any of claims 1 to 5~~ claim 1 wherein R₂ is optionally substituted monocyclic or bicyclic heteroaryl.

8. (Currently Amended) The ~~use~~method as claimed in ~~any of claims 1 to 5~~ claim 1 wherein R₂ is optionally substituted furyl, thienyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, indolyl or benzofuranyl.

9. (Currently Amended) The ~~use~~method as claimed in ~~any of the preceding claims~~ claim 1 wherein optional substituents present in R₂ are selected from C₁-C₃ alkyl, C₁-C₃ alkoxy, chloro, bromo, fluoro, trifluoromethyl, and carboxamide groups.

10. (Currently Amended) The ~~use~~method as claimed in ~~any of claims 1 to 8~~ claim 1 wherein optional substituents present in R₂ are selected from methyl, ethyl, methoxy, ethoxy, cyclopropyl, chloro, bromo, fluoro, trifluoromethyl, and carboxamide groups -CONR^AR^B where R^A and R^B are independently hydrogen, methyl or ethyl.

11. (Currently Amended) The ~~use method~~ as claimed in ~~any of claims 1 to 5~~ claim 1 wherein R₂ is 2-furyl, 5-methyl-2 furyl, 2-thiazolyl, 4-methyl-2-thiazolyl, phenyl, or o-methyl-phenyl.
12. (Currently Amended) The ~~use method~~ as claimed in ~~any of the preceding claims~~ claim 1 wherein R₃ is H, C₁-C₆alkyl, C₃-C₆ cycloalkyl, halo substituted C₁-C₆alkyl, or halogen.
13. (Currently Amended) The ~~use method~~ as claimed in ~~any of claims 1 to 11~~ claim 1 wherein R₃ is H, methyl, ethyl, n- or isopropyl, cyclopropyl, n-, sec- or tert-butyl, trifloromethyl, chloro, bromo or fluoro.
14. (Currently Amended) The ~~use method~~ as claimed in ~~any of the preceding claims~~ claim 1 wherein R₄ is C₁-C₆alkyl, substituted by aryl or heteroaryl, the said aryl or heteroaryl ring being optionally substituted.
15. (Currently Amended) The ~~use method~~ as claimed in ~~any of claims 1 to 13~~ claim 1 wherein R₄ is arylmethyl or heteroarylmethyl, the said aryl or heteroaryl ring being optionally substituted.
16. (Currently Amended) The ~~use method~~ as claimed in ~~any of the preceding claims~~ claim 1 wherein R₄ is aryl or heteroaryl or includes an aryl or heteroaryl ring, said ring being selected from optionally substituted phenyl, pyridyl, furanyl, thienyl, isoxazolyl, thiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, benzimidazolyl, indolyl, benzthiazolyl, benzthiadiazolyl, quinolyl, and isoquinolyl.
17. (Currently Amended) The ~~use method~~ as claimed in ~~any of claims 1 to 13~~ claim 1 wherein R₄ is aryl or heteroaryl or includes an aryl or heteroaryl ring, said ring being selected from optionally substituted phenyl, pyridyl, imidazolyl, pyrazolyl, and isoxazolyl.
18. (Currently Amended) The ~~use method~~ as claimed in ~~any of claims 14 to 17~~ claim 14 wherein optional substituents are selected from C₁-C₆alkyl, C₁-C₃ alkoxy, chloro, bromo,

fluoro, trifluoromethyl, $-NR^A R^B$, $-CONR^A R^B$, $-NR^A COR^B$ where R^A and R^B are independently hydrogen or C_1 - C_3 alkyl or together form an optionally substituted 5 or 6-membered heterocyclic ring.


19. (Currently Amended) The ~~use method~~ as claimed in ~~any of the preceding claims~~ claim 1 wherein R_5 is hydrogen.

20. (Currently Amended) The ~~use method~~ as claimed in ~~any of claims 1 to 13~~ claim 1 wherein R_4 and R_5 taken together with the nitrogen to which they are attached form a saturated 5 or 6-membered heterocyclic ring, optionally benz-fused.

21. (Currently Amended) The ~~use method~~ as claimed in ~~any of claims 1 to 13~~ claim 1 wherein R_4 and R_5 taken together with the nitrogen to which they are attached form a dihydroindolyl, dihydroisoindolyl, tetrahydroquinolyl or tetrahydroisoquinolyl ring system.

22. (Canceled)

23. (Currently Amended) A compound of formula (I); ~~as defined in any of claims 1 to 21;~~



wherein

R_1 is optionally substituted C_1 - C_6 alkyl, C_2 - C_6 alkenyl, or C_2 - C_6 alkynyl, or $-NR_6 R_7$, $-OR_8$, $-SR_9$ or halogen;

R_2 is optionally substituted 5-membered heteroaryl;

R_3 is H; optionally substituted C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 alkynyl, or C_3 - C_7 cycloalkyl, halogen; OH or OR_{10} ;

R₄ is H, optionally substituted C₁-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, C₃-C₇ cycloalkyl, aryl or heteroaryl.

R₅ is H or optionally substituted C₁-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, or C₃-C₇cycloalkyl; or R₄ and R₅ together form a 5 or 6-membered heterocyclic ring;

R₆ is H or optionally substituted C₁-C₃alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, or C₃-C₇ cycloalkyl;

R₇, R₈, R₉ and R₁₀ are optionally substituted C₁-C₃alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, or C₃-C₇ cycloalkyl or

R₆ and R₇ together form a 5 or 6-membered heterocyclic ring;

or a pharmaceutically acceptable salt or prodrug thereof.

24. (Original) A compound as claimed in claim 23 wherein the compound is selected from any of the compounds as shown in Table 1.

25. (Currently Amended) ~~For use in therapy~~ A therapy comprising administering an effective amount of a compound as claimed in ~~claims 23 or 24~~ claim 23.

26. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim 23 ~~or claim 24~~ in combination with a pharmaceutically acceptable carrier or excipients.

27. (Currently Amended) ~~A use as claimed in any of claims 1 to 21 or a method as claimed in claim 22-1~~ wherein said receptors are adenosine receptors.

28. (Currently Amended) ~~A use as claimed in any of claims 1 to 21 or a method as claimed in claim 22-1~~ wherein said receptors are adenosine A_{2A} receptors.

29. (Currently Amended) ~~A use as claimed in any of claims 1 to 21 or a method as claimed in claim 22-1~~ wherein the disorders are selected from movement disorders; anxiety disorders; affective disorders; central and peripheral nervous system degenerative disorders; schizophrenia; cognitive and memory impairment disorders; attention disorders; central nervous system injury; cerebral ischaemia; myocardial ischaemia; muscle ischaemia; sleep

disorders; eye disorders; cardiovascular disorders; and diabetes.

30. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein the movement disorder is selected from Parkinson's disease, progressive supernuclear palsy, Huntingtons disease, muhiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism and spasticity.

31. (Currently Amended) A ~~use or~~ method as claimed in claim 29 ~~or claim 30~~, wherein the disorder is a movement disorder and the compound of formula (I) is used or administered together with L-DOPA or a dopamine agonist.

32. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein the anxiety disorder is selected from panic disorder, agorophobia, obsessive compulsive disorder, social phobia, post traumatic stress disorder, generalised anxiety disorder and specific phobia.

33. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein said affective disorder is selected
from bipolar disorder, seasonal affective disorder, depression, manic depression, atypical depression and monodepressive disease.

34. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein said central and peripheral nervous system degenerative disorder is selected from corticobasal degeneration, demyelinating disease, Freidrich's ataxia, motoneurone disease, multiple system atrophy, myelopathy, radiculopathy, peripheral neuropathy, systemic lupus erythamatosi, granulomatous disease, olivo-ponto-cerebellar atrophy, progressive pallidal atrophy, progressive supranuclear palsy and spasticity.

35. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein said cognitive and/or memory . impairment disorder is selected from dementia, Alzheimers Disease, Frontotemporal dementia, multi-infarct dementia, AIDS dementia, dementia associated with Huntingtons Disease, Lewy body dementia, senile dementia, age-related memory

impairment, cognitive impairment associated with dementia, Korsakoff syndrome, dementia pugilans;

36. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein attention disorder is selected from attention-deficit hyperactivity disorder (ADHD), attention deficit disorder, minimal brain dysfunction, brain-injured child syndrome, hyperkinetic reaction childhood and hyperactive child syndrome.

37. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein said central nervous system injury is selected from traumatic brain injury, surgical trauma, raised intracranial pressure, cerebral oedema, hydrocephalus and spinal cord injury.


38. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein said cerebral ischaemia is transient ischaemic attack, stroke, subarachnoid haemorrhage, cerebral vasospasm, perinatal asphyxia, drowning, cardiac arrest or subdural haematoma.

39. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein the sleep disorder is selected from hypersomnia, narcolepsy and restless legs syndrome.

40. (Currently Amended) A ~~use or~~ method as claimed in claim 29 wherein the eye disorder is selected from retinal ischaemia-reperfusion injury and diabetic neuropathy.

41. (Canceled)

42. (Currently Amended) A method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I); ~~as set out in any of claims 1 to 21~~



wherein

R₁ is optionally substituted C₁-C₆alkyl, C₂-C₆alkenyl, or C₂-C₆alkynyl, or -NR₆R₇, -OR₈, -SR₉ or halogen;

R₂ is optionally substituted aryl or heteroaryl attached via a carbon atom;

R₃ is H; optionally substituted C₁-C₆alkyl, C₂-C₆alkenyl, C₂alkynyl, or C₃-C₇ cycloalkyl, halogen; OH or OR₁₀;

R₄ is H, optionally substituted C₁-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, C₃-C₇ cycloalkyl, aryl or heteroaryl.

R₅ is H or optionally substituted C₁-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, or C₃-C₇cycloalkyl; or R₄ and R₅ together form a 5 or 6-membered heterocyclic ring;

R₆ is H or optionally substituted C₁-C₃alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, or C₃-C₇ cycloalkyl;

R₇, R₈, R₉ and R₁₀ are optionally substituted C₁-C₃alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, or C₃-C₇ cycloalkyl or

R₆ and R₇ together form a 5 or 6-membered heterocyclic ring;

or a pharmaceutically acceptable salt or prodrug thereof.